ERBB2 and breast carcinoma: Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination With Fulvestrant in Postmenopausal Patients With HR+, HER2- Breast Cancer That Had Progressed During or After Prior Endocrine Therapy13